A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
12/2006
12/14/2006	WO2006133353A2 Methods of facilitating neural cell survival using non-peptide and peptide bdnf neurotrophin mimetics
12/14/2006	WO2006133326A1 Inhibitors of hcv replication
12/14/2006	WO2006133303A1 Alpha 7 nicotinic receptor selective ligands
12/14/2006	WO2006133261A2 Organic compounds
12/14/2006	WO2006133257A2 Use of cis-epoxyeicosatrienoic acids and inhibitors of soluble epoxide hydrolase to reduce cardiomyopathy
12/14/2006	WO2006133242A2 Azinone and diazinone v3 inhibitors for depression and stress disorders
12/14/2006	WO2006133231A2 Treatment for neurodegenerative diseases
12/14/2006	WO2006133199A2 Treatment with sigma receptor agonists post-stroke
12/14/2006	WO2006133198A2 Hsv drugs
12/14/2006	WO2006133197A1 Compositions and methods for treating sleep disorders
12/14/2006	WO2006133128A2 INHIBITION OF EPAC, PHOSPHOLIPASE Cϵ, AND PHOSPHOLIPASE D TO TREAT PAIN
12/14/2006	WO2006133098A2 Pharmacological chaperones for treating obesity
12/14/2006	WO2006133097A2 Use of alternating amine and non-amine bisphosphonate combinations for treating osteoporosis
12/14/2006	WO2006133092A1 Methods of treating cancer and other conditions or disease states using lfmau and ldt
12/14/2006	WO2006133046A2 Nanoparticulate imatinib mesylate formulations
12/14/2006	WO2006133045A1 Nanoparticulate benidipine compositions
12/14/2006	WO2006133006A2 1-methyl-1h-pyrazole-4-carboxamides useful as cancer chemotherapeutic agents
12/14/2006	WO2006132959A2 Inhibition of thrombin generation
12/14/2006	WO2006132950A2 Therapeutic polymers and methods of use
12/14/2006	WO2006132947A2 3-acyl coumarins, thiochromones and quinolones and therapeutic uses thereof
12/14/2006	WO2006132930A1 Combination of pyrimidylaminobenzamide compounds and imatinib for treating or preventing proliferative diseases
12/14/2006	WO2006132928A2 Methods and compositions for treating inflammation
12/14/2006	WO2006132879A2 Soft gel capsules containing polymethoxylated flavones and palm oil tocotrienols
12/14/2006	WO2006132870A1 Ophthalmic solution with a flavoring agent
12/14/2006	WO2006132868A1 Ophthalmic solution with a flavoring agent as a dosing indicator and method for indicating dosage of an ophthalmic solution
12/14/2006	WO2006132837A1 l-HYDROXYCYCLOALKANECARBOXAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS
12/14/2006	WO2006132811A2 Ampa receptor potentiators
12/14/2006	WO2006132739A2 Novel chemical compounds
12/14/2006	WO2006132675A2 Xiap-targeted prostate cancer therapy
12/14/2006	WO2006132647A2 Antimicrobial copolymers and uses thereof
12/14/2006	WO2006132583A1 Method and means for preventing and inhibiting respiratory disease, atherosclerosis and osteoporosis caused by chlamydia pneumoniae infection
12/14/2006	WO2006132515A1 Agent for the treatment of vaginitis containing mandelic acid as an active ingredient
12/14/2006	WO2006132460A1 Agent for the prevention and treatment of liver diseases containing pyrazolopyrimidine derivative
12/14/2006	WO2006132442A1 Vitamin d-like compound
12/14/2006	WO2006132440A1 Solid preparation
12/14/2006	WO2006132438A1 1,3-benzothiazinone derivative and use thereof
12/14/2006	WO2006132436A1 Heterocyclic compound
12/14/2006	WO2006132432A1 Therapeutic agent for neurogenic pain
12/14/2006	WO2006132430A1 Process for production of polymerized coordination compound of platinum complex
12/14/2006	WO2006132401A1 Method for evaluation of compound using rsk1
12/14/2006	WO2006132360A1 Sugar-coated tablet
12/14/2006	WO2006132342A1 Eye drop containing roflumilast
12/14/2006	WO2006132310A1 Liquid for preventing tissue adhesion and method of preventing tissue adhesion
12/14/2006	WO2006132307A1 Stabilized milnacipran formulation
12/14/2006	WO2006132295A1 Regulator of aldosterone receptor
12/14/2006	WO2006132275A1 Prophylactic and/or therapeutic agent for motor disorder
12/14/2006	WO2006132251A1 Prophylactic/therapeutic agent for adult t cell leukemia
12/14/2006	WO2006132236A1 Mobilizer of leukocyte and/or hematopoietic stem/progenitor cell
12/14/2006	WO2006132223A1 Anti-hypertensive composition
12/14/2006	WO2006132217A1 Crystal of salt of benzimidazole compound
12/14/2006	WO2006132204A1 Transcription factor decoy
12/14/2006	WO2006132197A1 HETEROCYCLIC COMPOUND HAVING TYPE I 11β HYDROXYSTEROID DEHYDROGENASE INHIBITORY ACTIVITY
12/14/2006	WO2006132192A1 Novel 2-quinolone derivative
12/14/2006	WO2006132177A1 Human cell differentiation inducer and product containing the same
12/14/2006	WO2006132091A1 Novel triglyceride reducing agent
12/14/2006	WO2006132042A1 Nutritional supplement powder and fat for food or medicine
12/14/2006	WO2006132033A1 Novel triterpenic acid derivative and preparation for external application for skin comprising the same
12/14/2006	WO2006131807A1 Preparation of 3-amino-4,5-disubstituted-pyrazole derivatives
12/14/2006	WO2006131790A2 Oral ribavirin pharmaceutical composition
12/14/2006	WO2006131737A2 Method and composition for treating inflammatory disorders
12/14/2006	WO2006131713A1 Cyclohexanesulfonyl derivatives as glyt1 inhibitors to treat schizophrenia
12/14/2006	WO2006131711A1 Cyclohexanesulfonyl derivatives as glyt1 inhibitors to treat schizophrenia
12/14/2006	WO2006131653A1 Composition based on an avermectine and metronidazole in particular for treating rosacea
12/14/2006	WO2006131652A1 Composition based on an avermectine and benzoyl peroxide in particular for treating rosacea
12/14/2006	WO2006131651A2 Avermectin and hydrocortisone-based composition, in particular for roracea treatment
12/14/2006	WO2006131649A2 Use of fumagillin and the derivatives thereof to increase the bioavailability of the macrocyclic lactones
12/14/2006	WO2006131632A1 Hydrates of alkaline-earth salts of irbesartan and the preparation thereof
12/14/2006	WO2006131591A2 An entacapone-containing oral dosage form
12/14/2006	WO2006131566A2 Oral ribavirin pharmaceutical compositions
12/14/2006	WO2006131525A1 3 -aryloxy- 8 -aza-bicyclo [3.2.1.] oct- 6- ene derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
12/14/2006	WO2006131524A1 Novel n-phenyl-piperidine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
12/14/2006	WO2006131519A1 Quinoline derivatives as antibacterial agents
12/14/2006	WO2006131491A1 Polymorphs of ethyl 3-[(2-{[4-(hexyloxycarbonylamino-iminomethyl)phenylamino]methyl}-1-methyl-1h-benzimidazole-5-carbonyl)pyridin-2-ylamino]propionate
12/14/2006	WO2006131484A1 Indole derivatives having antitumor activity
12/14/2006	WO2006131482A1 Cinnamic, phenylpropiolic and phenylpropanoic acid derivatives useful as anti-tumour agents
12/14/2006	WO2006131481A1 Production of solid solutions based on poorly-soluble active substances by a short-term heating and rapid drying
12/14/2006	WO2006131452A1 SULFONAMIDE DERIVATIVES USEFUL AS LIVER CARNITINE PALMITOYL TRANSFERASE (L-CPTl) INHIBITORS
12/14/2006	WO2006131401A2 Controlled release of a drug through skin on the basis of a topical composition comprising a drug, a film-forming silicone and at least one volatile solvent
12/14/2006	WO2006131398A2 Inhibitors of soluble adenylate cyclase
12/14/2006	WO2006131394A1 Immediate-release and high-drug-load pharmaceutical formulations of micronised (4-chlorophenyl)[4-(4-pyridylmethyl)phthalazin-1-yl] and salts thereof
12/14/2006	WO2006131393A1 Immediate-release and high-drug-load pharmaceutical formulations of non-micronised (4-chlorophenyl)[4-(4-pyridylmethyl)phthalazin-1-yl] and salts thereof
12/14/2006	WO2006131392A1 Pharmaceutical compositions of a neuroactive steroid and uses thereof
12/14/2006	WO2006131340A2 Pyrrolones that act as peptide deformylase (pdf) inhibitors
12/14/2006	WO2006131336A1 POLYCYCLIC OXADIAZOLES OR I SOXAZOLES AND THEIR USE AS SlP RECEPTOR LIGANDS
12/14/2006	WO2006131326A2 Novel use of (-)-epigallocatechin gallate
12/14/2006	WO2006131303A2 Peptide deformylase (pdf) inhibitors 4
12/14/2006	WO2006131296A1 Substituted n-benzo [d] isoxazol-3-yl-amine derivatives as inhibitors of mglur5, serotonine (5-ht) and noradrenaline receptors, and the use thereof for producing medicaments
12/14/2006	WO2006131262A1 Mucoadhesive xyloglucan-containing formulations useful in medical devices and in pharmaceutical formulations
12/14/2006	WO2006131233A1 Benzooxazole-2-on derivatives as lipase and phospholipase inhibitors
12/14/2006	WO2006131232A1 Benzothiazol-2-on derivatives as lipase and phospholipase inhibitors
12/14/2006	WO2006131231A1 Azolopyridine-2-on derivatives as lipase and phospholipase inhibitors
12/14/2006	WO2006131200A1 2,6 quinolinyl derivatives, processes for preparing them and their use as medicament
12/14/2006	WO2006131186A1 Oxindoles as kinase inhibitors
12/14/2006	WO2006131003A1 Angiogenesis inhibitors
12/14/2006	WO2006130994A1 Synthesis of glycerolipid carbamates and dicarbamates and their use as antitumor compounds
12/14/2006	WO2006130986A1 Azacyclohexane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase
12/14/2006	WO2006130982A1 Compositions and methods for enhancing nitric oxide delivery
12/14/2006	WO2006130949A1 Anti amyloid-related disease molecules and their uses
12/14/2006	WO2006130943A1 Respirable dried powder formulation comprising drug loaded nanoparticles
12/14/2006	WO2006130901A1 Control of metabolic abnormalities

1 ... 3964 3965 3966 3967 3968 3969 3970 3971 3972 3973 3974 3975 3976 3977 3978 3979 3980 3981 3982 3983 3984 ... 7860